MedTrace Logo

Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

NCT03184194 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-05-22

No results posted yet for this study

Summary

Evaluation of the effect of nivolumab and daratumumab with or without low-dose cyclophosphamide in patients with relapsed/refractory multiple myeloma.

Conditions

Interventions

DRUG

nivolumab-daratumumab

nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression

DRUG

nivolumab-daratumumab with low-dose cyclophosphamide

nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Meander Medical Center

    collaborator OTHER

  • St. Antonius Hospital

    collaborator OTHER

  • Isala

    collaborator OTHER

  • Albert Schweitzer Hospital

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Rijnstate Hospital

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Niels van de Donk, MD PhD · VUmc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-21
Primary Completion
2023-01-25
Completion
2024-01-25

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03184194 on ClinicalTrials.gov